Aurobindo Pharma has secured a significant deal, acquiring Lannett Company, a US-based generic pharmaceutical firm, for $250 million. According to a BSE filing, the transaction has received approval from the US Federal Trade Commission (FTC) and is expected to close by the end of June 2026.
This acquisition will expand Aurobindo’s product portfolio and manufacturing capabilities in the US.
The acquisition of Lannett will add a US-based manufacturing facility to Aurobindo’s network, with the capacity to produce approximately 4 billion doses annually.
This enhanced capacity aligns with US policy priorities aimed at improving supply chain resilience and increasing domestic pharmaceutical production. The deal is expected to be immediately accretive to Aurobindo’s earnings per share.
As part of the agreement, Aurobindo will acquire Lannett’s manufacturing site in Seymour, Indiana, which specializes in the development and commercialization of complex, non-opioid controlled substances.
The transaction is anticipated to generate meaningful cost efficiencies, SG&A synergies, and operational integration advantages. This will enhance Aurobindo’s position in the pharmaceutical sector, supporting sustainable long-term growth.
The acquisition represents a highly compelling strategic and financial opportunity for Aurobindo, accelerating its revenue growth and strengthening its US-based manufacturing capabilities.
With this deal, Aurobindo reinforces its commitment to expanding its presence in the global pharmaceutical market. This order adds to Aurobindo’s growing portfolio of complex generics and controlled substances.
This acquisition is a significant milestone for Aurobindo, demonstrating its ability to identify and capitalize on strategic opportunities. The deal is expected to have a positive impact on Aurobindo’s financial performance, driving growth and increasing its competitiveness in the pharmaceutical sector.
Disclaimer: The information provided is for educational purposes only and does not constitute financial advice. We are not registered financial advisors. Please conduct your own research and consult a qualified advisor before making investment decisions. Any investment decisions you make based on this information are solely at your own risk.
